Pulse Biosciences earnings on deck as PFA technology faces test By Investing.com

Pulse Biosciences Inc. is expected to report its second-quarter results after market close on Thursday, with investors keenly watching the performance of its Nanosecond Pulsed Field Ablation (PFA) technology. Analysts anticipate a loss of 29 cents per share on revenue of $533,330, reflecting sequential revenue growth but a wider loss compared to the previous quarter. The focus will be on whether the strong clinical data from initial studies can be replicated in larger pivotal trials and the trajectory of commercial adoption for its novel technology.